Rubicon Research IPO Details
The Rubicon Research IPO is a book build issue with a total issue size of ₹1377.5 cr, comprising of fresh issue of 10309278 equity shares., and a offer for sale of 18092762 equity shares. Rubicon Research IPO opened for subscription on Oct 09, 2025 and closed on Oct 13, 2025. Rubicon Research IPO is set price band at ₹461 to ₹485 per share, with a lot size of 30 shares. Minimum investment for Retail investors was ₹14,550.00 (at the upper price band) to apply for one lot.
The basis of allotment got finalized on Oct 14, 2025, and listed on both the NSE and BSE on Oct 16, 2025.
MUFG Intime India Private Limited has been appointed as the registrar. IIFL Capital Services Limited, Axis Capital Limited, JM Financial Limited and SBI Capital Markets Limited are the Book Running Lead Manager for the issue.
Before investing in the Rubicon Research IPO, investors should review the company's financial performance, business objectives, and risk factors mentioned in the offer documents and apply before the subscription window closes.
- Price Band
- ₹ 461 – 485
- Lot Size
- 30
- Issue Size
- ₹1377.5 Cr
- Minimum Investment
- ₹14550 (30 Shares)
- Listing Date
- 16 October 2025
Current GMP
₹120 (+24.74%)
*Info is indicative. Not an Investment Advice. Grey market trading is unregulated.
About Rubicon Research Limited
Incorporated in 1999, Rubicon Research Limited is a pharmaceutical company engaged in the development, manufacturing, and commercialization of differentiated formulations.
As of June 30, 2025, the company had a portfolio of 72 active Abbreviated New Drug Application (ANDA) and New Drug Application (NDA) products approved by the US FDA. Out of these, 66 products were commercialized, catering to a US generic pharmaceutical market valued at USD 2,455.7 million, with Rubicon Research contributing USD 195 million in revenue during Fiscal 2024.
The company also has 17 new products awaiting US FDA ANDA approval and 63 additional products under various stages of development as of the same date.
Rubicon Research markets over 350 SKUs to 96 customers, including three major US wholesalers that collectively account for more than 90% of wholesale drug distribution in the country. Its customer base also includes group purchasing organizations (GPOs), national and regional pharmacy chains, and managed care organizations.
Beyond the US, Rubicon Research has registered or filed 48 product applications across Australia, the United Kingdom, Singapore, Saudi Arabia, and the United Arab Emirates, through direct operations or third-party distribution partners, with commercial launches expected upon regulatory approvals. The company additionally provides contract manufacturing services to select customers in India, Australia, and New Zealand.
Rubicon Research operates three manufacturing facilities in India and two US FDA-inspected R&D centers, located in India and Canada.
Rubicon Research IPO Promoters
- General Atlantic Singapore RR Pte. Ltd.
- Pratibha Pilgaonkar
- Sudhir Dhirendra Pilgaonkar
- Parag Suganchand Sancheti
- Surabhi Parag Sancheti
- Sumant Sudhir Pilgaonkar
Promoters Holding
Holding Pre Issue
77.67%
Holding Post Issue
0.00%
Rubicon Research IPO Objective
The Company Rubicon Research IPO proposes to utilise the Net Proceeds from the Issue towards the following objects.
- Prepayment or scheduled repayment of all or a portion of certain outstanding borrowings availed by our Company
- Funding inorganic growth through unidentified acquisitions and other strategic initiatives and General corporate purposes
Address / Contact Info
Rubicon Research Ltd.
MedOne House, B-75,
Road No. 33, Wagle Estate,
Thane, Maharashtra, 400604
Phone: 022 61414000
Email: investors@rubicon.co.in
Website: https://www.rubicon.co.in/
IPO Snapshot
Book Running Lead Managers
- IIFL Capital Services Limited
- Axis Capital Limited
- JM Financial Limited
- SBI Capital Markets Limited
Disclaimer: This data is for informational purposes only and does not constitute investment advice. Figures shown are illustrative sample data.
Frequently Asked Questions
Everything you need to know before applying to an IPO.
Rubicon Research IPO is a Book-building IPO with a total issue size of ₹1377.5 crore. The Rubicon Research IPO price band is ₹461 to 485 per share. The Rubicon Research IPO subscription opens on Thu, Oct 9, 2025, and closes on Mon, Oct 13, 2025. The Rubicon Research IPO will be listed on the BSE,NSE. MUFG Intime India Private Limited is the registrar for the Rubicon Research IPO.
The Rubicon Research IPO opens on Thu, Oct 9, 2025 and closes on Mon, Oct 13, 2025
Rubicon Research IPO Price Band is ₹461 to 485 per share.
Rubicon Research IPO lot size is 30 shares, Retail investors need a minimum investment of ₹14550 based on the upper price band
The minimum investment for Rubicon Research IPO is ₹14550, based on one lot of 30 shares at the upper price band of ₹485 per share.
Investors can apply for the Rubicon Research IPO through the ASBA (Application Supported by Blocked Amount) facility offered by their bank or through UPI using a SEBI-registered broker or trading app. Select the desired lot size, enter your bid within the price band, and submit the application before Mon, Oct 13, 2025. The application amount remains blocked until the Rubicon Research IPO allotment is finalized.
Rubicon Research IPO issue size is ₹1377.5 crores.
Rubicon Research IPO allotment date is Wed, Jul 1, 2026.
The registrar for Rubicon Research IPO is MUFG Intime India Private Limited. Investors can go to MUFG Intime India Private Limited website to check Rubicon Research IPO allotment status, refund processing, and other IPO-related information.
The Rubicon Research IPO GMP (Grey Market Premium) is ₹120 as of Thu, Oct 16, 2025. Based on the upper price band of ₹485 per share, the estimated Rubicon Research IPO listing price is ₹605, indicating a potential listing gain of approximately 0% over the issue price.